Sanofi

Sanofi US Announces Honors Cross-disease Registry Idea

Pharmaceutical packaging firms, patients, medical staff and others could benefit from the registry, designed to foster collaboration in medical research.

Sanofi US announced today that Registries for All Diseases has been selected as the winner of the Collaborate Activate Innovation Challenge.

No votes yet

Sanofi, Bristol-Myers Squibb to Restructure Alliance

The two pharma firms altered their partnership following the loss of exclusivity of some drugs in many major markets.

Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

No votes yet

Kentucky Attorney General Announces Settlement With Sanofi-Aventis

The state has recovered another $2.29 million on behalf of its Medicaid program regarding claims of fraudulent pricing practices.

Attorney General Jack Conway today announced that he has recovered another $2.29 million on behalf of the Kentucky Medicaid program following a settlement with Aventis Pharmaceuticals, Inc. and Aventis Behring, LLC, also known as ZLB Behring, Inc. Both drug companies are now owned by Sanofi-Aventis U.S. LLC. This is the latest in a number of settlements in so-called Average Wholesale Price (AWP) lawsuits filed by the Office of the Attorney General against 47 of the nation's largest pharmaceutical companies.

No votes yet

Sanofi Announces U.S. Launch of iBGStar Blood Glucose Monitoring System

The system, which combines a blood glucose meter and Diabetes Manager App, connects directly to an iPhone for patient feedback and data management.

Sanofi US announced today that the iBGStar Blood Glucose Monitoring System, consisting of the iBGStar blood glucose meter and iBGStar Diabetes Manager App, is commercially available in the U.S. iBGStar  is the first Food and Drug Administration (FDA) cleared blood glucose meter that directly connects to the iPhone and iPod touch, offering accurate blood glucose monitoring that seamlessly integrates into the lives of people with diabetes.

No votes yet

Sanofi Announces New Long Term Objectives

Commenting on the Group’s outlook, Sanofi CEO Christopher A. Viehbacher said: “Sanofi has undergone an impressive transformation over the last two and a half years and the patent cliff is now almost behind us. While 2012 will be impacted by the loss of exclusivity of Plavix® and Avapro® in the U.S., Sanofi is set to embark upon a period of consistent and sustainable growth.

Your rating: None Average: 4 (1 vote)
Syndicate content